Researchers have developed a new blood test that can measure the severity of Alzheimer's disease by detecting specific protein fragments linked to tau tangles in the brain, according to a study published in JAMA and led by Lund University and Banner Health.

The test targets a biomarker called eMTBR-tau, which directly reflects the amount of tau tangles that have accumulated. This is a key feature of Alzheimer's disease, but until now, assessing tau tangle buildup required invasive procedures or expensive brain imaging.

"This is a significant breakthrough in Alzheimer's research," said Niklas Mattsson-Carlgren, a professor at Lund University and a neurology specialist at Skåne University Hospital, in a university press release. "A simple blood test enables an assessment of how widespread tau tangles are in the brain, and to do so on a large scale."

The new test differs from the widely used blood biomarker p-tau217, which rises early in the disease and indicates amyloid plaque accumulation but provides limited information about later-stage tau tangles. According to Lund University, the eMTBR-tau test can distinguish between early and late stages of the disease more clearly.

The study involved 728 participants, including 521 brain donors from two US research programmes and 207 participants from cohorts in Sweden and Canada. The blood test results closely matched those obtained using advanced mass spectrometry methods, and post-mortem brain tissue analysis confirmed that eMTBR-tau levels corresponded to total tau tangle accumulation.

For university students studying neuroscience, medicine, or related fields, this development highlights how blood-based biomarkers are becoming more precise tools for diagnosing and staging neurodegenerative diseases. The method could eventually simplify clinical trials by providing a less expensive, scalable way to monitor disease progression.

The test uses an immunoassay — an antibody-based method that requires only a small blood sample — making it suitable for large-scale use. Previously, measuring eMTBR-tau required specialised techniques only available in advanced laboratories.

"A simple test that can be used on a very large scale to determine the extent of tau tangle accumulation in the brain is a major step forward in our understanding of Alzheimer's disease," said Nicholas Ashton, the study's corresponding author and head of Banner's Fluid Biomarker Program at the Banner Sun Health Research Institute, in the release.

According to Lund University, further studies are needed before the test can be introduced into routine clinical practice. The researchers plan to continue validating the method for clinical use.

Funding for the Swedish contributions came from the Swedish Research Council, the Swedish Brain Foundation, the Alzheimer's Foundation, ALF funding, MultiPark, the Mats Paulsson Foundation, and the Rönnström family.